Viatris Inc. Stock price

Equities

VTRS

US92556V1061

Pharmaceuticals

Real-time Estimate Cboe BZX 12:13:34 2024-03-01 pm EST 5-day change 1st Jan Change
12.58 USD +1.66% Intraday chart for Viatris Inc. -7.43% +15.65%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2023 15.43B Sales 2024 * 15.23B Capitalization 14.84B
Net income 2023 54M Net income 2024 * 1.94B EV / Sales 2023 0.84 x
Net Debt 2023 * 16.19B Net Debt 2024 * 13.5B EV / Sales 2024 * 1.86 x
P/E ratio 2023
217 x
P/E ratio 2024 *
8.67 x
Employees 38,000
Yield 2023 *
3.94%
Yield 2024 *
3.98%
Free-Float 97.93%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.65%
1 week-7.41%
1 month+5.10%
3 months+34.75%
6 months+15.07%
Current year+14.22%
More quotes
1 week
11.96
Extreme 11.96
13.55
1 month
11.44
Extreme 11.44
13.62
Current year
10.79
Extreme 10.79
13.62
1 year
8.74
Extreme 8.74
13.62
3 years
8.42
Extreme 8.42
16.29
5 years
8.42
Extreme 8.42
29.30
10 years
8.42
Extreme 8.42
76.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 22-12-28
Director of Finance/CFO 63 20-11-15
President 63 20-11-15
Members of the board TitleAgeSince
Chairman 56 20-11-15
Director/Board Member 68 20-11-15
Director/Board Member 66 20-11-15
More insiders
Date Price Change Volume
24-03-01 12.52 +1.21% 3 336 072
24-02-29 12.37 +0.65% 21,664,070
24-02-28 12.29 -7.11% 26,685,568
24-02-27 13.23 -1.49% 18,161,819
24-02-26 13.43 -0.74% 11,668,003

Delayed Quote Nasdaq, February 29, 2024 at 04:00 pm EST

More quotes
Viatris Inc. (Viatris) is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, as well as the Company's ARV franchise. Its portfolio comprises over 1,400 approved molecules across a range of key therapeutic areas, including key brands and complex generics. It operates around 40 manufacturing sites worldwide, which produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients. Its products include Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen Auto Injector, Fraxiparine and Yupelri.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
12.37 USD
Average target price
11.95 USD
Spread / Average Target
-3.39%
Consensus
  1. Stock
  2. Equities
  3. Stock Viatris Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW